AstraZeneca has announced that from 1 January TAGRISSO (osimertinib) will have its PBS listing expanded to include the first-line treatment of a form of lung cancer.
Clinicians and consumers welcome earlier access to lung cancer therapy
December 21, 2020 Latest News
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 31 October
October 31, 2025 - - Podcast -
Aroa Biosurgery appoints Paul Shearer to Board as John Pinion retires
October 31, 2025 - - Australian Biotech -
Immuron provides update on U.S. clinical trials for Travelan and IMM-529
October 31, 2025 - - Australian Biotech -
Firebrick Pharma launches new Nasodine Throat Spray for international markets
October 31, 2025 - - Australian Biotech -
Amplia Therapeutics begins trading on U.S. OTCQB Venture Market
October 31, 2025 - - Australian Biotech -
DHL Supply Chain opens New Zealand’s most advanced life sciences and healthcare logistics facility
October 31, 2025 - - Latest News -
The continued 'false framing' aims to make us feel guilty for wanting more on health
October 31, 2025 - - Latest News
